Celltrion Presents Clinical Data on 'CT-P13 SC' at the Largest US Digestive Disease Conference

CT-P13 SC: Presentation of Japanese Phase 3 Trial and Post-hoc Analysis Results

Celltrion announced on the 7th that it participated in the 2026 Digestive Disease Week (DDW), held in Chicago, USA, from June 2nd to 5th (local time), and once again demonstrated the competitiveness of its autoimmune disease treatment 'CT-P13 SC (Remsima SC, marketed as Zymfentra in the US, active ingredient infliximab),' earning high praise from international medical professionals.

DDW is the largest international academic conference in the field of digestive diseases, including gastroenterology, hepatology, and endoscopy. Each year, over 13,000 of the world’s leading scholars attend to share the latest clinical research and therapeutic development trends.

From June 2 to 5 (local time), at the Digestive Disease Week (DDW) 2026 held in Chicago, USA, global medical professionals and industry stakeholders visited the Celltrion booth to receive explanations about key products, including Zymfentra. Celltrion

At this year's event, Celltrion operated its own booth to actively promote the brand’s competitiveness and successfully concluded a wide range of academic and marketing activities, including two poster presentations, a symposium, and a Product Theater session.

On the first day of the conference, the results of a 44-week phase 3 clinical trial of CT-P13 SC conducted in Japan for patients with Crohn's disease (CD) were unveiled for the first time, drawing significant attention from attending medical professionals. The study showed that patients who achieved clinical remission with the existing intravenous (IV) formulation maintained excellent tolerability and safety after switching to the subcutaneous (SC) formulation. This reaffirmed the convenience, efficacy, and safety of CT-P13 SC.

In addition, a post-hoc analysis of a 102-week global phase 3 clinical trial of CT-P13 SC in patients with Crohn's disease and ulcerative colitis (UC) was also presented via poster. In this study, patients who received at least 16 weeks of placebo following discontinuation of IV therapy were administered 240mg of CT-P13 SC, resulting in rapid recovery of clinical response and sustained efficacy through week 102. These findings suggest that high-concentration CT-P13 SC administration could be an effective treatment strategy not only for simple formulation switching, but also for patients who experience unavoidable gaps in therapy, garnering strong support from the medical community onsite.

On June 3rd, a symposium titled "Subcutaneous Therapies in IBD: Evidence, Patient Selection, and Practical Approaches to Optimizing Outcomes" was held. Sponsored by Celltrion, this Continuing Medical Education (CME) session saw global IBD experts deeply discuss optimal use strategies for SC formulations based on the latest guidelines and real-world clinical data, drawing considerable attention from local prescribers.

On the final day of the conference, Celltrion hosted a Product Theater session titled "Understanding Zymfentra: The only FDA-approved subcutaneous infliximab offering a different therapeutic approach in UC and CD maintenance," which highlighted Zymfentra's differentiated therapeutic strategies and captivated the attention of attendees.

Celltrion expects that these research results, along with various other clinical findings, will further boost the prescription credibility of CT-P13 SC. In fact, based on accumulated clinical data, CT-P13 SC achieved sales of 839.4 billion won in the global market last year, up about 40% compared to 2024. Given this growth momentum, the company forecasts that annual sales will comfortably surpass 1 trillion won this year.

This robust growth is backed by remarkable achievements in key markets such as Europe and the United States. In the five major European countries (EU5), Celltrion surpassed a 30% market share for the first time as of the third quarter last year, solidifying its strong presence. In the United States, Zymfentra recorded its highest-ever monthly prescription volume in January this year, growing more than threefold (213%) year-on-year, further confirming its rapid prescription growth.

A Celltrion representative stated, "At this year's DDW, the world’s leading gastroenterology conference, we once again validated the outstanding therapeutic efficacy and safety of CT-P13 SC, and directly experienced the strong trust of global medical professionals onsite. Moving forward, we will continue to secure robust clinical data that reflect the needs of the medical field and implement differentiated, tailored marketing strategies to further accelerate prescription growth worldwide."

This content was produced with the assistance of AI translation services.